360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Flagship Ventures

Type: Company

Name: Flagship Ventures

First reported 17 hours ago - Updated 17 hours ago - 1 reports

Atlas Venture

Eight companies Spark Capital has backed in Boston

Boston-based Spark Capital may be best known for making investments outside its home city, such as Tumblr and Twitter.But Spark also ranks among the VC firms which frequently back Boston-area startups: Spark invested $25 million into Massachusetts-based ... [Published New York Business Journal - 17 hours ago]

Entities: Spark Capital, Boston (Massachusetts, United States), Flagship Ventures, Highland Capital Partners, Atlas Venture

First reported 18 hours ago - Updated 18 hours ago - 1 reports

Form SC 13D Receptos, Inc. Filed by: Flagship Ventures Fund 2007, L.P.

StreetInsider.com - Form SC 13D Receptos, Inc. Filed by: Flagship Ventures Fund 2007, L.P. ... [Published Street Insider - 18 hours ago]

Entities: Flagship Ventures, Receptos Inc

First reported 19 hours ago - Updated 19 hours ago - 1 reports

SC 13D - Flagship Ventures Fund 2007, L.P. (0001508052) (Filed by)

Document Format FilesSeq Description Document Type Size 1 SC 13D d540524dsc13d.htm SC 13D 131898 2 EX-99.1 d540524dex991.htm EX-99.1 5673 Complete submission text file 0001193125-13-227192.txt 139458 ... [Published SEC - 19 hours ago]

Entities: Flagship Ventures

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Novartis AG

Novartis taps synthetic biology to speed vax development

The evolution of vaccine manufacturing methods is closely linked to the products themselves. In the period of vaccine innovation that followed World War II, investments spurred on evolution of production, but a lull began in the 1970s. Now the pace of ... [Published FierceVaccines - May 16 2013]

Entities: Novartis AG, Vaccine, Massachusetts Institute of Technology, Influenza

First reported May 15 2013 - Updated May 15 2013 - 1 reports

VC Investment: Not Quite Dead?

Venture investment in some biotechnology specialties has more than doubled year-to-year during the first quarter, even as overall investment in the field continued to decline, according to a report released today.PricewaterhouseCoopers reported that investment ... [Published Genetic Engineering News - May 15 2013]

Entities: Biotechnology, Aisling Capital LLC, Boulder Ventures Limited

First reported May 09 2013 - Updated May 10 2013 - 1 reports

Receptos Flat In IPO

San Diego-based biopharmaceuticals developer Receptos is trading flat after its initial public offering, after pricing last night at $14.00 per share. The developer of biopharmaceuticals for treating immune and metabolic diseases priced at the low end ... [Published SoCalTech - May 09 2013]

Entities: Receptos Inc, IPOs, Biopharmaceuticals

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Genzyme Corp

Genzyme’s former CEO takes board seat at Moderna

Henri Termeer, retired chairman, president and CEO of Genzyme Corp., has joined Moderna Therapeutics' board of directors. Moderna Therapeutics has tapped Henri Termeer, the former chairman, president and CEO of Genzyme Corp., a Sanofi subsidiary, to join ... [Published Boston Business Journal - Apr 30 2013]

Entities: Genzyme Corp, Henri Termeer, ModeRNA Therapeutics, Messenger RNA

First reported Apr 30 2013 - Updated Apr 30 2013 - 2 reports

Supply Chains Are Orderly. Biotech Innovation Is Messy

Home » Blogs » I was intrigued by the concept of an “innovation supply chain” for biotech raised in last week’s Xconomy discussion with Noubar Afeyan of Flagship Ventures. The basic idea is that if there’s agreement about certain experiments, results, ... [Published BioPortfolio - Apr 30 2013]

Entities: Biotechnology, Invention, Noubar Afeyan, Flagship Ventures, Xconomy Inc

First reported Apr 28 2013 - Updated Apr 28 2013 - 1 reports

China Biotech In Review: WuXi PharmaTech Contributes To Syros Pharma Funding

By ChinaBio Today : Deals and Transactions Syros Pharmaceuticals, a Boston area startup, raised $30 million to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression (see story ). The WuXi ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 28 2013]

Entities: WuXi PharmaTech Cayman Inc, Biotechnology, China, Arch Venture Partners, Flagship Ventures

First reported Apr 22 2013 - Updated Apr 23 2013 - 1 reports

GlaxoSmithKline and Avalon Ventures Agree to Startup Collaboration

Bruce V. BigelowAvalon Ventures founder Kevin Kinsella has been saying for some time that pharmaceutical companies should be striking deals with VC firms that know how to organize biotech startups—and it now appears a Big Pharma was listening.The Wall ... [Published Xconomy - Apr 22 2013]

Entities: Avalon Ventures, Startup, GlaxoSmithKline plc

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

GSK $495 Million Deal To Spearhead Drug Discovery Start-Ups

In a deal worth just under $500 million, GlaxoSmithKline has confirmed they will partner with venture capitalists to kick start up to 10 drug-discovery firms.The collaboration has been designed so the GSK will support small start-up businesses set up ... [Published eyeforpharma.com - Apr 23 2013]

Entities: GlaxoSmithKline plc, Drug Discovery, Moncef Slaoui, Avalon Ventures, Venture capitalist

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

A Biotech Innovation Supply Chain: Reality or Fantasy?

Biotech has always been a bit like an open-air market bazaar. Now the industry needs to become a little more stable, more predictable. It ought to be part of something you could call an âinnovation supply chain.âAt least, thatâs the view of Noubar Afeyan, ... [Published Xconomy - Apr 22 2013]

Entities: Biotechnology, Supply Chain, Big Pharma

Quotes

"At the most fundamental, I think what's most exciting is a breakthrough recognition that the cellular process that we all learned about in freshman biochemistry for 50 years, that such a fundamental process is selectively regulated and is used by multiple different oncogenes and that they are druggable" Worland said

Effector Therapeutics snags $45M venture round from A-list backers [Published FierceBiotech - 22 hours ago]

...rationale for the encouraging effects shown in this preclinical MDS model", said Ravi Kumar, Ph D , Chief Scientific Officer of Acceleron. "The potential of ACE-536 to correct the anemia by targeting ineffective erythropoiesis is very exciting and applicable to other diseases, such as beta thalassemia, in which ineffective erythropoiesis leads to serious and chronic anemia and where there are few treatment options."

Acceleron’s ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th Internationa ... [Published Business Wire - May 10 2013]

...consumers will experience air-based food (chocolate shots are available through AeroDesigns’ website) and--eventually--air-based pharmaceuticals. "We can, with this process, deliver all the essential vitamins, the taste sensations,” says Edwards. “It’s a whole new way of putting active ingredients in the mouth without pills and a whole new way of eating, which is still kind of blue-sky."

Chewing and Swallowing Are So Yesterday [Published inc.com - May 10 2013]

...disease and symptoms suffered by patients with dry eye disease," said Abbie Celniker, PhD, Chief Executive Officer of Eleven Biotherapeutics. "With these data, we have successfully established that topical administration of EBI-005 is safe and well-tolerated in healthy volunteers, safety and tolerability are important criteria for patients who suffer from painful symptoms associated with ocular inflammation. We look forward to reporting data on our Phase 1b clinical study of EBI-055 in dry eye disease and moving expeditiously to advance into Phase 2 clinical studies in multiple ocular inflammatory diseases including continuation of the clinical program in dry eye disease as well as a new study in severe allergic conjunctivitis."

Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for T ... [Published Zecco - May 08 2013]

More Content

sort by: Date \| Relevance
Eight companies Spark Capital has backed in Boston [Published New York Business Journal - 17 hours ago]
Form SC 13D Receptos, Inc. Filed by: Flagship V... [Published Street Insider - 18 hours ago]
SC 13D - Flagship Ventures Fund 2007, L.P. (000... [Published SEC - 19 hours ago]
Effector Therapeutics snags $45M venture round ... [Published FierceBiotech - 22 hours ago]
Deals Of The Week Is Keeping Score – Valeant Wa... [Published The IN VIVO Blog - May 17 2013]
East Coast Life Sciences Roundup: Termeer, Atla... [Published Xconomy - May 17 2013]
Novartis taps synthetic biology to speed vax de... [Published FierceVaccines - May 16 2013]
VC Investment: Not Quite Dead? [Published Genetic Engineering News - May 15 2013]
Acceleron’s ACE-536 Preclinical Data Presentati... [Published Business Wire - May 10 2013]
Chewing and Swallowing Are So Yesterday [Published inc.com - May 10 2013]
Receptos Flat In IPO [Published SoCalTech - May 09 2013]
Biotech Receptos claims $73M IPO prize to fuel ... [Published FierceBiotech - May 09 2013]
Eleven Biotherapeutics Presents Data on EBI-005... [Published Zecco - May 08 2013]
BIND Therapeutics to Present at the UBS Global ... [Published Zecco - May 06 2013]
BIND Therapeutics and AstraZeneca Announce Worl... [Published Drugs.com - May 03 2013]
Acceleron and Shire Conclude Collaboration on A... [Published Business Wire - May 02 2013]
Genzyme’s former CEO takes board seat at Moderna [Published Boston Business Journal - Apr 30 2013]
Supply Chains Are Orderly. Biotech Innovation I... [Published BioPortfolio - Apr 30 2013]
Henri A. Termeer Joins Moderna Therapeutics Boa... [Published NewsBlaze - Apr 30 2013]
Supply Chains Are Orderly. Biotech Innovation I... [Published Xconomy - Apr 30 2013]
China Biotech In Review WuXi PharmaTech Contrib... [Published BioPortfolio - Apr 28 2013]
China Biotech In Review: WuXi PharmaTech Contri... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 28 2013]
GSK $495 Million Deal To Spearhead Drug Discove... [Published eyeforpharma.com - Apr 23 2013]
GlaxoSmithKline and Avalon Ventures Agree to St... [Published Xconomy - Apr 22 2013]
ASTRAZENECA PLC: AstraZeneca and BIND Therapeut... [Published 4 Traders - Apr 22 2013]
A Biotech Innovation Supply Chain: Reality or F... [Published Xconomy - Apr 22 2013]
BIND Therapeutics and AstraZeneca Announce Worl... [Published Yahoo! Finance - Apr 22 2013]
BIND Therapeutics and AstraZeneca Announce Worl... [Published Business Wire - Apr 22 2013]
LS9 Expands Operations at Its Florida Demonstra... [Published GlobeNewswire - Apr 17 2013]
Syros Pharmaceuticals Reports Publications in Cell [Published Individual.com - Apr 17 2013]

Blogs

sort by: Date \| Relevance
Deals Of The Week Is Keeping Score – Valeant Wa... [Published The IN VIVO Blog - May 17 2013] Whether the pastime is baseball, Broadway or the daytime soaps, the old adage is that you can’t keep track of the players without a scorecard. The M&A front involving specialty pharma and generic drug makers has become similarly frenzied, as Canada’s ...
Funding Daily: Peanut butter and banana sandwiches [Published Venturebeat - Apr 12 2013] Today’s funding daily is dedicated to peanut butter and banana sandwiches. Why? Because a startup that delivers homemade, organic, peanut butter and banana sandwiches to your door raised money. Not really. Rather, it is because this unfortunate writer ...
Pharma startup gets $30M for genetic cancer tre... [Published Venturebeat - Apr 12 2013] Syros Pharmaceuticals , a company that aims to revolutionize the treatment of cancer and other diseases, announced today it received $30 million in financing from Flagship Ventures and ARCH Venture Partners . This is the company’s first round ...
Uneasy Lies The Head That Wears a Financings of... [Published The IN VIVO Blog - Apr 05 2013] Compared to other types of financing, royalty-based deals in the biopharma world are rare. That’s because a company needs products with future revenue to parlay into a near-term lump sum, and the relative few companies that have such products often ...
Mascoma finally realizes going public is not a ... [Published Earth2Tech - Mar 28 2013] A little over a year and a half ago, Mascoma, which is a startup with aims to make next-generation cellulosic ethanol, filed to go public in a potentially $100 million IPO. In an article entitled “ Some red flags and numbers in Mascoma’s IPO filing ...

Press Releases

sort by: Date \| Relevance
Acceleron’s ACE-536 Preclinical Data Presentati... [Published Business Wire - May 10 2013]
Acceleron and Shire Conclude Collaboration on A... [Published Business Wire - May 02 2013]
BIND Therapeutics and AstraZeneca Announce Worl... [Published Business Wire - Apr 22 2013]
Moderna Announces $40 Million In Financing To A... [Published PR Newswire: Financial Services - Dec 06 2012]
TransMedics, Inc. Secures $36 Million Round of ... [Published Financial Services - Nov 27 2012]